Besides the above mentioned targets, many other MM-associated, but not entirely plasma cell, or MM-specific targets, such as NKG2D, CD56, Lewis-x, CD44v6 are evaluated for CAR T-cell therapy (42–44), with currently no reported outcomes of the latter three (NCT04097301, NCT03473496, NCT01716364). The gene discussed is NCAM1; the disease is Miyoshi myopathy.